PHIBRO ANIMAL HEALTH CORP (PAHC): M&A transaction — Phibro completes $350M acquisition of Zoetis' medicated feed additive portfolio

PHIBRO ANIMAL HEALTH CORP

Acquired >37 product lines across ~80 countries, six manufacturing sites in US, Italy, China, and >300 employees.
Funded with $350M cash: $189M Delayed Draw Term A-1 Loans and $161M A-2 Loans under existing credit agreement.
Expected to boost profitability, EBITDA margin, and be accretive to adjusted EPS; more details on Nov 7 Q1 call.
Portfolio complements Phibro's vaccines, nutritional specialties, and mineral nutrition.

item 2.01 item 9.01 item 2.03 item 7.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

PHIBRO ANIMAL HEALTH CORP completed an acquisition involving Zoetis Inc. for $350 million in cash (closed 2024-10-31).

Action: acquisition
Counterparty: Zoetis Inc.
Consideration: $350 million in cash
Closing: 2024-10-31

Exact text from the filing

and Sale Agreement (as amended, modified or supplemented, the “Purchase Agreement”) by and among Phibro and Zoetis. Phibro completed the acquisition at a purchase price of $350 million in cash, subject to certain adjustments set forth in the Purchase Agreement. The Company intends to file an amendment to this Form 8-K to file the financial statements and pro

View on SEC.gov

Browse all m&a transactions →

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001104659-24-113064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.